-
1por Baldassari, Ivan, Oliverio, Andreina, Krogh, Vittorio, Bruno, Eleonora, Gargano, Giuliana, Cortellini, Mauro, Casagrande, Alice, Di Mauro, Maria G., Venturelli, Elisabetta, Del Sette Cerulli, Daniela, Manuela, Bellegotti, Berrino, Franco, Pasanisi, Patrizia“…MeMeMe recruiting experience, highlighting strengths, limitations encountered and results is reported. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2“…We are conducting a Phase III trial on persons with metabolic syndrome to test the hypothesis that comprehensive lifestyle changes and/or metformin treatment prevents age-related chronic diseases (the MeMeMe trial, EudraCT number: 2012-005427-32, also registered on ClinicalTrials.gov [NCT02960711]). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3por Cortellini, Mauro, Casagrande, Alice, Fornaciari, Giuseppe, Del Sette, Daniela, Gargano, Giuliana, Di Mauro, Maria Gaetana, Saibene, Gabriella, Bruno, Eleonora, Villarini, Anna, Venturelli, Elisabetta, Berrino, Franco, Baldassari, Ivan, Oliverio, Andreina, Pasanisi, Patrizia“…OBJECTIVE: This paper describes a novel software created specifically for the management of a randomized trial of diet and metformin in people with metabolic syndrome (the Me.Me.Me. trial). METHODS: Me.Me.Me. is an ongoing phase III randomized controlled trial in healthy people with metabolic syndrome to test the hypothesis that comprehensive lifestyle changes and/or metformin can prevent age-related chronic non-communicable diseases. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4por Mondal, Dhrubajyoti, Majee, Mithun Chandra, Bhattacharya, Kisholoy, Long, Jérôme, Larionova, Joulia, Khusniyarov, Marat M., Chaudhury, Muktimoy“…[Image: see text] Five neutral bis(μ-phenoxido)dicopper(II) complexes, [Cu(2)(L(Me,Me,Me))(2)] (1), [Cu(2)(L(Me,Me,Et))(2)]·CH(2)Cl(2) (2), [Cu(2)(L(i-Pr,i-Pr,i-Pr))(2)]·2H(2)O (3), [Cu(2)(L(t-Bu,Me,i-Pr))(2)] (4), and [Cu(2)(L(t-Bu,t-Bu,i-Pr))(2)]·H(2)O (5) have been synthesized and characterized by single-crystal X-ray diffraction analyses, magnetic studies, and density functional theory (DFT) calculations, in which the ligands [H(2)L(Me,Me,Me) = N,N-bis(2-hydroxy-3,5-dimethylbenzyl)-N′,N′-dimethylethylene-1,2-diamine, H(2)L(Me,Me,Et) = N,N-bis(2-hydroxy-3,5-dimethylbenzyl)-N′,N′-dimethylethylene-1,2-diamine, H(2)L(i-Pr,i-Pr,i-Pr) = N,N-bis(2-hydroxy-3,5-diisopropylbenzyl)-N′,N′-diisopropylethylene-1,2-diamine, H(2)L(t-Bu,Me,i-Pr) = N,N-bis(2-hydroxy-3-tert-butyl-5-methylbenzyl)-N′,N′-diisopropylethylene-1,2-diamine, and H(2)L(t-Bu,t-Bu,i-Pr) = N,N-bis(2-hydroxy-3,5-di-tert-butylbenzyl)-N′,N′-diisopropylethylene-1,2-diamine] contain the same [O,N,N,O]-donor atoms combination but differ in substituents at phenol rings and at an amino nitrogen atom. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto